Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.
Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte.
Bienvenu J, et al. Among authors: casasnovas o.
Hematol J. 2001;2(6):378-84. doi: 10.1038/sj.thj.6200133.
Hematol J. 2001.
PMID: 11920277
Clinical Trial.